E-Paper
Novartis India says will continue to file for patents
Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the the Supreme Court rejected its plea for patent protection of its drug Glivec.
Updated on: Apr 1, 2013, 15:23:09 IST
Share via
Copy link
Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the the Supreme Court rejected its plea for patent protection of its drug Glivec.
Novartis India will also continue to invest there, but with caution, Ranjit Shahani, who is also the managing director of the company, told reporters after the Supreme Court judgment.
Earlier on Monday, the court dismissed Novartis' petition seeking patent protection for cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
Stay updated with the latest Business News, stock market updates, petrol and diesel prices, gold and silver rates, income tax updates and major developments from India and across the world.
